Subject index volume 119 (1997)

LETTERS

ELSEVIER

Cancer Letters 119 (1997) 255-258

Subject index Volume 119 (1997) lo-amino acid residue: Stromelysin-3 (ST3); Antibodies; RXKR sequences 119, 71

Benzo[u]pyrene; Leiomyosarcomas; Vanadiutn(II1) complexes; t cysteine; N-(2-mercaptopropionyl)-glycine; Wistar rats 119, 22 1

2-Deoxyglucoee; 185

Bile acids and salts: Breast; Electrolyte: Fibrocystic disease; I>ipoprotein 119, 21

Grp75; Heat shock proteins; Fibroblasts

&Hydtw&‘-deoxyguanosine; Flavonoid; peroxidation; Antioxidant effect 119, 99

119,

Free radical; Lipid

Advanced non-smah cell lung cancer; Mitomycin; Cisplatin; Etoposide 119, 237

Vindesine;

An&wide; Hepatocarcinogenesis; morpholine 119, 109

N-Nitroso-

Anthocyanins; ging 119. 37

Antimutagenic

Chemoprevention;

activity;

Free radicals

scaven-

Antibodies: Stromelysin-3 (ST3); lo-amino acid residue; RXKR sequences 119, 71 AntIcancer drug; p53 gene; MDRl tosis 119. 177 Antimutagenic ging 119, 37

activity;

gene; Drug resistance; Apop-

Anthocyanins;

Free radicals scaven-

Antioxidant effect; Flavonoid; 8-Hydroxy-2’-deoxyguanosine; Free radical; Lipid peroxidation 119, 99 Antioxidanta;

Suckling neonates; Lactating mice

119, 201

Apoptosis; Breast; Prostate; PC12; BODIPY ceramide Apoptosis; ~53 gene; MDRI drug 119, 177

119, 169

gene: Drug resistance: Anticancer

Apoptosis; Phloretin; Melanoma cells; Glucose transport; Protein kinase C 119,207 Artihcial neural networks; Breast cancer; Computer-assisted diagnosis; Evolutionary computation; Evolutionary programming 119, 93 Bcl-2 and cyclin ‘D’ expression; LDL; Receptor ‘C,; Lymphocytes: CML 119. 131

Biiharzia; Genetic polymorphism; CYP2D6; Bladder cancer: Cytochrome P-450 schistosoma; Genetic susceptibility; PCR; RFLP 119. 115 Bladder cancer; Genetic polymorphism; CYP2D6; Bilharzia; Cytochrome P-450 schistosoma; Genetic susceptibility: PCR: RFLP 119, 115 BODIPY ceramide; Breast; Prostate; PC12; Apoptosis Breast cancer; Computer-assisted diagnosis; Artificial works; Evolutionary computation; Evolutionary ming 119. 93

119. 169 neural netprogram-

Breast cancer; Soluble IL-6 receptor (IL-6sR): Soluble TNF receptors (sTNF-Rs); Polymotphonuclear cells (PMNsJ 119, 70 Breast; Bile acids and salts; Electrolyte; Fibrocysttc disease: Lipoprotein 119, 21 Breast; Prostate; PC12: Apoptosis; BODIPY ceramide

119. 169

Carcinoma: New anticancer agent; Mice: Ehrhch ascites; Sarcoma- 180; Dalton’s lymphoma; Tumour growth inhibition 119.7 CD44 expression; Metastases; Non small cell lung cancers 27 Cell deformability;

Docosahexaenoic acid: Metastasis

Chaperonin; Cisplatin; Oxaliplatin; proteins 119, 63 Chemoprevention; Amiloride; morpholine 119, 109

0304-3835/97/$17.00 0 1997 Elsevier Science Ireland Ltd. All rights reserved PII SO304-3835(97)00439-4

119, I63

Drug resistance: Heat shock

Hepatocarcinopenesis; h;-Nitroso-

Chemotherapy response: Glutathione: resistance 119, 157 Cis-diammInedichloroplatinum

119.

Urothelial

(II) (CDDR:

saucer; Drug

Drug resistance:

256

Subject index

Human maxillary carcinoma; Hyperthermia; Intracellular platinum uptake 119, 47

Ehrlich ascites; New anticancer agent; Mice; Carcinoma; Sarcoma-180; Dalton’s lymphoma; Tumour growth inhibition 119,7

Cisplatin; Advanced non-small cell lung cancer; Mitomycin; Vindesine; Etoposide 119, 237

Electrolyte; Bile acids and salts; Breast; Fibrocystic disease; Lipoprotein 119, 21

Cisplatin; Oxaliplatin; Drug resistance; Heat shock proteins; Chaperonin 119, 63

Etoposide; Advanced non-small cell lung cancer; Mitomycin; Vindesine; Cisplatin 119, 237

L-Cysteine; Benzo[a]pyrene; Leiomyosarcomas; Vanadium(II1) complexes; N-(2-mercaptopropionyl)-glycine; Wistar rats 119, 221

Evolutionary computation; Breast cancer; Computer-assisted diagnosis; Artificial neural networks; Evolutionary programming 119,93

CML; LDL; Receptor ‘Ck; Bcl-2 and cyclin ‘D’ expression; Lymphocytes 119, 131

Evolutionary programming; Breast cancer; Computer-assisted diagnosis; Artificial neural networks; Evolutionary computation 119, 93

Computer-assisted diagnosis; Breast cancer; Artificial works; Evolutionary computation; Evolutionary ming 119, 93

neural netprogram-

Fe-NTA toxicity; ture 119, 31

Oxidative

DNA

damage; Hepatocyte

cul-

Copper; Long-Evans Cinnamon (LEC) rat; Serum response factor (SRF) 119, 137

Fibroblasts; 185

Cultured human gastric cancer cell line; Cytoskeleton system; Metastasis model 119, 191

Fibrocystic disease; Bile acids and salts; Breast; Electrolyte; Lipoprotein 119, 21

Cyclooxygenase;

Flavonoid; 8-Hydroxy-2’-deoxyguanosine; oxidation; Antioxidant effect 119, 99

PGH synthase; ras gene

119, 87

CYF2D6; Genetic polymorphism; Bladder cancer; Bilharzia; Cytochrome P-450 schistosoma; Genetic susceptibility; PCR; RFLP 119, 115 Cytochrome P-450 schistosoma; Genetic polymorphism; CYP2D6; Bladder cancer; Bilharzia; Genetic susceptibility; PCR; RFLP 119, 115 Cytoskeleton system; Cultured human gastric cancer cell line; Metastasis model 119, 191 Dalton’s lymphoma; New anticancer agent; Mice; Ehrlich ascites; Carcinoma; Sarcoma-180; Tumour growth inhibition 119, 7 Docosahexaenoic 163

acid;

Cell

deformability;

Metastasis

119,

Drug resistance; Cisplatin; Oxaliplatin; Heat shock proteins; Chaperonin 119, 63 Drug resistance; Glutathione; Urothelial response 119, 157

cancer; Chemotherapy

Grp75; Heat shock proteins; 2-Deoxyglucose

119,

Free radical; Lipid per-

Free radical; Flavonoid; 8-Hydroxy-2’-deoxyguanosine; peroxidation; Antioxidant effect 119, 99

Lipid

Free radicals ity 119, 37

activ-

scavenging; Anthocyanins;

Antimutagenic

Genetic polymorphism; CYP2D6; Bladder cancer; Bilharzia; Cytochrome P-450 schistosoma; Genetic susceptibility; PCR; RFLP 119, 115 Genetic susceptibility; Genetic polymorphism; CYP2D6; Bladder cancer; Bilharzia; Cytochrome P-450 schistosoma; PCR; RFLP 119, 115 Glucose transport; Phloretin; Apoptosis; Melanoma cells; Protein kinase C 119, 207 Glutathione peroxidase; Glutathione; Glutathione reductase; Glutathione S-transferase; Lung cancer 119, 13 Glutathione reductase; Glutathione; Glutathione peroxidase; Glutathione S-transferase; Lung cancer 119, 13

Drug resistance; Human maxillary carcinoma; Cis-diamminedichloroplatinum (II) (CDDP); Hyperthermia; Intracellular platinum uptake 119,47

Glutathione S-transferase; Glutathione; Glutathione reductase; Glutathione peroxidase; Lung cancer 119, 13

Drug resistance; p53 gene; MDRl tosis 119. 177

Glutathione; Glutathione reductase; Glutathione peroxidase; Glutathione S-transferase; Lung cancer 119, 13

gene; Anticancer drug; Apop-

757

Subject index

Glntathione; resistance

Urothelial 119, 157

Growth inhibition;

cancer; Chemotherapy response; Drug

Melanoma; Interferons; Resistance

Grp75; Heat shock proteins; 2-Deoxyglucose; 185

119, 227

Fibroblasts

119,

RAZZ; Human breast cancer: Prognostic marker; Met&&: progression 119, 149 Lactating mice; Antioxidants: Suckling neonates LDL; Receptor ‘C,; B&2 cytes: CML 119, 131

and cyciin

‘Tumor

1E9. 201

‘D’ expresslo”:

Lympho-

HZ9 gene; Insulin-like growth factor II (ZGF2); Loss of imprinting (LOI); Hepatocellular carcinoma (HCC); Hep3B 119, 143

Leiomyosarcomas; Benzo[a]pyrene; Vanadium(I11) complexes; I.cysteine; N-(2.mercaptopropionyl)-glycine: Wlstar eats 119. 21-l

Heat shock proteins; Cisplatin; Oxaliplatin; Drug resistance; Chaperonin 119. 63

Levofloxacin;

Heat shock proteins; Grp75; 2-Deoxyglucose; 185

Fibroblasts

119.

Hep3B; Insulin-like growth factor II (ZGF2); HI9 gene; Loss of imprinting (LOI); Hepatocellular carcinoma (HCC) 119, 143 Hepatitis B virus DNA integration; Hepatitis C virus; 119, 5.3

Hepatocellular

carcinoma;

Ofloxacin; MTT assay; Telomerase

119. 2 13

Lipid peroxidation; Flavonoid; 8-Hydroxy-2’-deoxy_euanosine: Free radical; Antioxidant effect 119, 99 Lipoprotein; Bile acids and salts; Breast: Electra!) W: Fibrocystic disease 119. 2 I Long-Evans Copper

Cinnamon (LEC) rat: Serum re~ponw factor ISRF):

119, 137

Hepatitis C virus; Hepatocellular DNA integration 119. 53

carcinoma; Hepatitis B virus

Loss of imprinting (LOI): Insulin-like growth factor 11 (IGF2); Hi9 gene; Hepatocellular carcinoma (HCC); Hep3)< 119. 143

Hepatocarcinogewsis; Amiloride; morpholine 119, 109

Chemoprevention; N-Nitroso-

Lung cancer; Glutathione; Glutatbione reductase; Glutathione peroxidase: Glutathione S-transferase 119. 13

Hepatocelhdar carcinoma (HCC); Insulin-like growth factor II (ZGF?): HZ9 gene; Loss of imprinting (LOI); Hep3B 119, 143 Hepatocelhdar carcinoma; DNA integration 119, 53 Hepatocyte culture; city 119, 31

Hepatitis C virus; Hepatitis B virus

Oxidative

DNA

damage; Fe-NTA

toxi-

Lymphocytes; LDL; Receptor ‘Ck; Bcl-2 and cyciin ‘D’ expression: CML 119, 131 MDRl gene: p53 gene: Drug resistance; Anticanci‘r drug: Apoptosih 119. 177 Melanoma cells; Phloretin: Apoptosis: Glucose transport; Protein kinase C 119, 207 Melanoma:

Human breast cancer; Prognostic marker; Metastasis; NAZI; Tumor progression 119. 149 Human maxillary carcinoma; Drug resistance; Cis-diamminedichloroplatinum (II) (CDDP); Hyperthermia; Intracellular platinum uptake 119, 47

Interferons; Resistance: Growth inhibition

119. 227

N-(2-Mercaptopropionyl)~giycine; Benzo[alpyrene: Leromyosarcomas; Vanadium(II1) complexes; L-cysteine: Wlstar rats 119, 221

Metastases: CD44 expression; Non small cell lung cancer:,

119,

27

Hypertbermia: Drug resistance; Human maxillary carcinoma; Cisdiamminedichloroplatinum (II) (CDDP): Intracellular platinum uptake 119, 47

Metastasis model; Cultured human gastric cancer ccl1 line; E’vtoskeleton system 119. 191

InsulinFlike growth factor II (ZGF2); HI9 gene; Loss of imprinting (LOI): Hepatccellular carcinoma (HCC); Hep3B 119, 143

Metastasis; Human breast cancer: Prognosric marker; Tumor progression 119. 149

Interferons;

Mice; New anticancer agent: Ehrlich ascites; Cxcinoma: Sarcoma180: Dalton’s lymphoma: Tumour growth inhibition 119. 7

Melanoma; Resistance; Growth inhibition

119, 227

Intracellular platinum uptake; Drug resistance; Human maxillary carcinoma: Cis-diamminedichloroplatinum (CDDP); (11) Hyperthermia 119. 47

Metastasis: Docosahexaenoic acid: Cell deformability

119. 163 /CA/l:

Mitomyein: Advanced non-small ccl1 lung cancer: Vindesinr. c’isplatin; Etoposide 119, 237

258

Subject index

MTT assay; Ofloxacin; Levofloxacin;

Telomerase

119, 213

New anticancer agent; Mice; Ehrlich ascites; Carcinoma; Sarcoma- 180; Dalton’s lymphoma; Tumour growth inhibition 119,7

RPLP Genetic polymorphism; CYP2D6; Bladder cancer; Bilharzia; Cytochrome P-450 schistosoma; Genetic susceptibility; FCR 119, 115

RKKR sequences; Stromelysin-3 (ST3); lo-amino acid residue; 119, 71

N-Nitrosomorphoibte; Amiloride; Hepatocarcinogenesis; Chemoprevention 119, 109

Antibodies

Non smalI cell lung cancers: CD44 expression; Metastases

Sarcoma-l(U); New anticancer agent; Mice; Ehrlich ascites; Carcinoma; Dalton’s lymphoma; Tumour growth inhibition 119, 7

119,

27

OiIoxacin; Levofloxacin; MTT assay: Telomerase

Serum responsefactor (SRP); Long-Evans Cinnamon (LEC) rat;

119, 213

Copper

119, 137

OxaIipIatin; Cisplatin; Drug resistance; Heat shock proteins; Chaperonin 119, 63

Signal transduction; Thyroid cancer; Protein kinase C 119, 1

Oxidative DNA damage; Fe-NTA ture 119, 31

Rs); Polymorphonuclear

p53 gene; MDRl tosis 119, 177

toxicity;

Hepatccyte

cul-

gene; Drug resistance; Anticancer drug; Apop-

PC12; Breast; Prostate; Apoptosis; BODIPY ceramide

119, 169

PCR, Genetic polymorphism; CYP2D6; Bladder cancer; Bilharzia; P-450 schistosoma; Cytochrome Genetic susceptibility; RFLP 119, 115 PGH synthase; rus gene; Cyclooxygenase

Soluble TNF receptors (sTNFcells (PMNs); Breast cancer 119, 79

Soluble TNF receptors (sTNP-Rs); Soluble IL-6 receptor (ILcells (PMNs); Breast cancer 119, 79

6sR); Polymotphonuclear

Stromelyshr3 (ST3); lo-amino acid residue; Antibodies; RXKR sequences 119, 71 Suckling neonates; Antioxidants; Lactating mice

119,201

Telomerase; Ofloxacin; Levofloxacin; MIT assay 119, 213 Thyroid cancer; Signal transduction; Protein kinase C 119, 1

119, 87

Phloretin; Apoptosis; Melanoma cells; Glucose transport; Protein kinase C

Soluble IL-6 receptor (IL&R);

119, 207

Tumor progression; Human breast cancer; Prognostic marker; 119, 149

Metastasis; KAIl

Polymorphonuclear cells (PMNs); Soluble IL-6 receptor (IL6sR); Soluble TNF receptors (sTNF-Rs); Breast cancer 119, 79

Tumour growth inhibition; New anticancer agent; Mice; Ehrlich ascites; Carcinoma; Sarcoma-18O; Dalton’s lymphoma 119, 7

Prognostic marker; Human breast cancer; Metastasis; KAII; Tumor progression 119, 149

resistance

Prostate; Breast; PC12; Apoptosis; BODIPY ceramide

119, 169

Protein klnaae C; Phloretin; Apoptosis; Melanoma cells; Glucose transport

119, 207

Protein kinase; Thyroid cancer; Signal transduction C 119, 1 rus gene; PGH synthase; Cycloqxygenase

119, 157

Vanadimu(IH) complexes; Benzo[a]pyrene; Leiomyosarcomas; Lcysteine; N-(2-mercaptopropionyl)-glycine; Wistar rats 119, 221 Vindesine; Advanced non-small cell lung cancer; Mitomycin; Cisplatin; Etoposide 119, 237 Wistar rats; Benzo[a]pyrene;

119, 87

Receptor ‘Ck; LDL; Bcl-2 and cyclin ‘D’ expression; Lymphocytes; CML 119, 131 Resistance; Melanoma; Interferons; Growth inhibition

Urotheiiai cancer; Glutathione; Chemotherapy response; Drug

119, 227

complexes; 221

L-cysteine;

Leiomyosarcomas; Vanadium(III) N-(2-mercaptopropionyl)-glycine 119,